[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myopia-progressive\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myopia-progressive":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,43,73,98,124,148,172,192],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100613267","evaluation-of-the-safety-and-efficacy-of-the-ddc-dual-control-technology-spectacle-lenses-in-delaying-the-progression-of-myopia-a-randomized-controlled-trial-100613267",false,"NCT07264361","Evaluation of the Safety and Efficacy of the D.D.C Dual-control Technology Spectacle Lenses in Delaying the Progression of Myopia: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Age between 6 and 14 years;\n* Cycloplegic spherical equivalent refraction between -1.50 D and -5.00 D with astigmatism ≥ -1.50 D in both eyes;\n* Absolute interocular difference in spherical equivalent refraction ≤ 1.50 D;\n* Binocular best-corrected visual acuity ≥ 1.0;\n* Intraocular pressure between 10 and 21 mmHg in both eyes;\n* Volunteer to participate in this clinical trial with signature of the informed consent form.\n\nExclusion Criteria:\n\n* History of eye injury or intraocular surgery or ocular trauma;\n* Clinically abnormal slit-lamp findings;\n* Abnormal fundus examination;\n* Presence of ocular diseases such as cataract, glaucoma, fundus pathology, ocular trauma, manifest strabismus, or any other condition affecting visual function;\n* Systemic diseases causing low immunity (such as diabetes, Down's syndrome, rheumatoid arthritis, psychotic patients or other diseases that researchers think are not suitable for wearing glasses);\n* Participation in a drug clinical trial within 3 months or a device clinical trial within 1 month prior to enrollment;\n* Participation in any myopia control clinical trial within the past 3 months and a history of myopia control interventions (e.g., orthokeratology, atropine);\n* Only one eye meeting the inclusion criteria;\n* Inability to attend regular ophthalmic examinations.","ALL","8 Years","12 Years",{"count":19,"type":20},316,"ESTIMATED","INTERVENTIONAL",[23],"NA","The burden of myopia among Chinese children and adolescents is severe and trending toward younger ages, making control of myopia progression a public health priority. Current mainstream strategies include optical interventions, pharmacologic therapy, and environmental measures. Among these strategies, spectacle designs based on optical defocus-such as defocus-incorporated multiple-segment (DIMS) lenses-have demonstrated efficacy; however, the effect of such designs may attenuate over time because of \"defocus adaptation.\" To address this limitation, D.D.C dual-control spectacles employ a densely staggered microlens layout, a gradient-defocus architecture, and an added peripheral \"fogging zone\" to disrupt the spatial distribution of defocus cues and reduce contrast, thereby delaying adaptation and enhancing myopia-control efficacy.\n\nThe present study therefore proposes a 24-month prospective randomized controlled trial in Guangzhou, enrolling eligible myopic adolescents. The trial will first compare 12-month outcomes between D.D.C-A lenses and single-vision lenses, followed by a crossover and alternating-wear phase, to systematically evaluate the safety and efficacy of the D.D.C technology in slowing myopia progression.",[26],"Myopia, Progressive",[28,29],"Defocus diffusion composite technology","Myopia control","NOT_YET_RECRUITING","2026-03-11",{"date":33,"type":34},"2026-03-12","ACTUAL",{"date":36,"type":20},"2026-03-30",{"date":38,"type":20},"2027-12-20",{"name":40,"class":41},"Zhongshan Ophthalmic Center, Sun Yat-sen University","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":15,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100618327","multicenter-rct-led-red-light-dose-response-in-myopia-progression-control-100618327","NCT07330180","Multicenter RCT: LED Red Light Dose-Response in Myopia Progression Control","Multicenter, Open-Label, Parallel-Group, Randomized Controlled Study Comparing the Dose-Response Relationship of LED Red Light in Controlling Myopia Progression","Inclusion Criteria:\n\n* Aged 6 to 14 years old, regardless of gender;\n* After cycloplegic autorefraction, monocular or binocular spherical equivalent refraction (SER) meets: -6.00D ≤ SER ≤ -1.00D, and binocular best-corrected visual acuity (BCVA) ≥ 0.8 (logMAR 0.1; Snellen 20\u002F25);\n* Binocular anisometropia ≤ 1.50D; astigmatism ≤ 2.50D;\n* Able to understand the purpose of the study, willing to participate in this clinical verification, sign the informed consent form personally or through their legal guardian, and cooperate with the entire trial process (12 months).\n\nExclusion Criteria:\n\n* Photophobia or allergy to cycloplegic agents (e.g., tropicamide or cyclopentolate);\n* Received any of the following myopia control measures within one month (including but not limited to): low-concentration atropine eye drops, orthokeratology lenses, myopia control-related frame glasses, low-level red light therapy, defocus soft contact lenses, or defocus RGP lenses;\n* Subjects with ocular diseases that may affect visual acuity or refractive error (e.g., lens disorders such as cataracts, glaucoma, macular degeneration, corneal diseases, uveitis, retinal detachment, severe vitreous opacity, etc.);\n* Neurological diseases (previous convulsion history, epilepsy, tic disorders, central nervous system developmental abnormalities) or mental and psychological diseases;\n* Systemic diseases: immune system diseases, central nervous system diseases, Down syndrome, asthma, severe cardiopulmonary function impairment, severe liver and kidney dysfunction, acute or chronic sinusitis, or diabetes mellitus;\n* Binocular manifest strabismus or any other pathological changes of the eyeball or acute inflammatory ocular diseases;\n* Subjects deemed inappropriate by the investigator.",true,"6 Years","14 Years",{"count":54,"type":20},364,[23],"The goal of this clinical trial is to verify the effectiveness and safety of non-laser LED red light combined with defocus lens therapy for controlling myopia progression and evaluate the impact of different intervention durations in 6-14 years old children and adolescents with myopia (spherical equivalent refraction: -6.00D ≤ SER ≤ -1.00D), regardless of gender. The main questions it aims to answer are:\n\n\\[primary hypothesis or outcome measure 1\\]: Does the combination of Yingtong Vision Rehabilitation Instrument (non-laser LED red light) and Hoya DIMS defocus lens show non-inferior effectiveness to Hoya DIMS defocus lens alone in controlling 6-month axial length change? \\[primary hypothesis or outcome measure 2\\]: Do different single intervention durations (2min, 3min, 4min) of non-laser LED red light affect the effectiveness (e.g., axial length change at multiple time points, 12-month SER change) and safety of the combined therapy? If there is a comparison group: Researchers will compare Test Group A (2min PBM therapy + DIMS lenses), Test Group B (3min PBM therapy + DIMS lenses), Test Group C (4min PBM therapy + DIMS lenses), and Control Group D (DIMS lenses alone)\\] to see if the combined therapy has similar or better myopia control effects and comparable safety, and to identify the optimal intervention duration.\n\nParticipants will:\n\nComplete screening examinations (axial length, refractive error, visual acuity, IOP, fundus photography, OCT, etc.) and sign the informed consent form.\n\nBe randomly assigned to one of the four groups and receive the corresponding intervention (use the Yingtong Vision Rehabilitation Instrument as per group-specific duration twice a day, with ≥4-hour interval, plus DIMS lenses; or only DIMS lenses).\n\nAttend regular follow-up visits at 30 days, 3 months, 6 months, 9 months, and 12 months for efficacy and safety assessments (including repeated ocular examinations and adverse event reporting).\n\nCooperate with the entire 12-month trial process and comply with the device usage specifications and follow-up requirements.",[58,26],"Myopia",[58,60,61,62],"Children","Axial Length","Red-light Therapy","2025-12-29",{"date":65,"type":34},"2026-01-09",{"date":67,"type":20},"2026-01-01",{"date":69,"type":20},"2027-04-30",{"name":71,"class":41},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",7,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":50,"sex":15,"minAge":80,"maxAge":17,"enrollmentInfo":81,"targetDuration":4,"studyType":21,"phases":83,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":42},"100545990","phase-3-study-to-evaluate-the-efficacy-of-alleance-atropine-sulfate-001-as-a-treatment-to-delay-myopia-and-axial-ocular-elongation-in-children-100545990","NCT06389110","Study to Evaluate the Efficacy of Alleance® (Atropine Sulfate 0.01%) as a Treatment to Delay Myopia and Axial Ocular Elongation in Children.","Phase III Clinical Study to Evaluate the Efficacy of Alleance® (Atropine Sulfate 0.01%) as a Treatment to Delay the Progression of Myopia and Axial Ocular Elongation in Children.","Inclusion Criteria:\n\n* Children aged between 3 to 12 years\n* Male or female sex.\n* The parent(s) or legal guardian(s) must voluntarily give their signed informed consent.\n* From the age of 7 years and older, the subject's willingness to participate in the research study will be expressed in writing. In the case of subjects under 7 years of age, only the signature of the informed consent by the parent(s) or legal guardian(s) will be required, provided that the subject's verbally expressed will is respected.\n* Ability and willingness to comply with the scheduled visits, treatment plan and other study procedures.\n* Female subjects, who have already presented their menarche, must have a negative urine pregnancy test at the time of screening.\n* Female subjects who have already experienced menarche should secure a method of contraception for the duration of the study. Acceptable contraceptive methods include abstinence (defined as abstinence from heterosexual intercourse from study entry until completion) or use of a highly effective contraceptive method, including hormonal contraception, barrier methods or intrauterine device).\n* Refractive error of spherical equivalent between -0.50 to -6.00 D in each eye, measured by autorefraction and cycloplegic retinoscopy.\n* Astigmatism less than -1.50 D in each eye, measured by autorefraction and retinoscopy.\n* Spherical equivalent anisometropia ≤ 1.50 D measured by autorefraction and cycloplegic retinoscopy.\n* Best corrected visual acuity (BCVA) normal for age.\n* Normal binocular function and stereopsis for age.\n* Normal intraocular pressure (\\\u003C 21 mmHg).\n* Gestational age ≥ 32 weeks and birth weight \\> 1500 g.\n\nExclusion Criteria:\n\n* Allergy to atropine or any of the components of the investigational products.\n* Previous or current use of atropine, orthokeratology lens or other optical methods for myopia control (bifocal, progressive, multifocal, or defocusing air or contact lenses). Only prior or current use of frame lenses or monofocal contact lenses for the correction of myopic or myopic\u002Fastigmatic refractive error will be allowed.\n\nHistory or current history of amblyopia or manifest strabismus, including intermittent tropia.\n\n* Heart rate \\> 120 beats per minute persistently (for more than 10 minutes) at the time of screening\u002Fbaseline visit.\n* History of any disease or syndrome predisposing the subject to severe myopia (Marfan syndrome, Stickler syndrome, retinopathy of prematurity, etc.).\n* History of serious systemic disease that, in the investigator's judgment, would make the subject ineligible (e.g., cardiac, endocrine, respiratory, neurologic \\[infantile cerebral palsy\\], Down syndrome, etc.).\n* History or current history of glaucoma or ocular hypertension.\n* History of any refractive ocular anatomical anomaly (keratoconus, lenticonus, spherophakia, aphakia, etc.).\n* History of ocular diseases, excluding myopia (corneal alterations\u002Fopacities, cataract, retinal alterations, inflammatory diseases, etc.).\n* History of any type of ocular surgery.\n* For female subjects who have presented their menarche: being pregnant or breastfeeding.\n* Having participated in clinical research studies 30 days prior to inclusion in the present study.\n* Previous participation in this study.\n* Present unresolved ocular lesions or trauma at the time of study entry.\n* Present active inflammatory or infectious ocular disease at the time of study entry.\n* Having undergone surgical procedures, not ophthalmologic, within the last 3 months.\n* Chronic use of any topical or systemic antimuscarinic\u002Fanticholinergic medication (atropine, scopolamine, tropicamide) within 21 days prior to screening, and\u002For anticipated need for its chronic use during the study period (more than 7 consecutive days in a month or more than 30 days total in a year). The use of cycloplegic drops for ophthalmologic examination is allowed.\n* Be or have an immediate family member (e.g., parent\u002Flegal guardian or sibling) who is part of the research site or sponsor´s staff.\n\nElimination Criteria:\n\n* Withdrawal of their consent to participate in the study (informed consent form).\n* Occurrence of a serious adverse event, whether related or not to the interventions, that in the opinion of the principal investigator (PI) and\u002For the sponsor, could affect the patient's fitness to safely continue with the study procedures.\n* Non-tolerability or hypersensitivity to any of the compounds used during the tests -(fluorescein, tetracaine).\n* Non-tolerability or hypersensitivity to any of the drugs under investigation.\n* Adherence \\\u003C 80% determined by the subject's diary and corroborated by the final weight of the research products (RP) compared to the initial weight.","3 Years",{"count":82,"type":20},123,[84],"PHASE3","Phase III clinical study to evaluate the efficacy of Alleance® (atropine sulfate 0.01%) ophthalmic solution through the incidence of unexpected adverse events, changes in Best Corrected Visual Acuity (BCVA), changes in intraocular pressure, changes in the amplitude of accommodation, compared to placebo, as a treatment to delay the progression of myopia and axial ocular elongation in children.",[58,26],"RECRUITING","2025-03-18",{"date":90,"type":34},"2025-03-21",{"date":92,"type":34},"2025-03-15",{"date":94,"type":20},"2027-10-30",{"name":96,"class":97},"Laboratorios Sophia S.A de C.V.","INDUSTRY",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":50,"sex":15,"minAge":16,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":21,"phases":108,"briefSummary":109,"conditions":110,"keywords":111,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":42},"100547264","to-evaluate-the-efficacy-and-safety-of-an-defocus-lens-in-slowing-the-progression-of-myopia-100547264","NCT06405711","To Evaluate the Efficacy and Safety of an Defocus Lens in Slowing the Progression of Myopia","To Evaluate the Efficacy and Safety of an Defocus Lens in Slowing the Progression of Myopia：a Prospective Study","Inclusion Criteria:\n\n* The subjects had spherical RE of -1.00 to -6.00 D, astigmatism ≤ 1.50 D, anisometropia ≤ 1.50 D\n* the best corrected visual acuity in the left and right eyes subjective optometry is greater than or equal to 1.0\n\nExclusion Criteria:\n\n* Candidate subjects were excluded from the study if they had strabismus, ocular limitations, or systemic abnormalities affecting vision and ocular motility","13 Years",{"count":107,"type":20},138,[23],"To confirm the efficacy of DIMS lenses in controlling myopia progression, we planned a prospective, single-centre, randomised, double-blind, controlled, non-inferiority clinical study.",[26],[112,113,114],"myopia","axial length","defocus","2024-05-05",{"date":117,"type":34},"2024-05-08",{"date":119,"type":20},"2024-05",{"date":121,"type":20},"2026-12",{"name":123,"class":41},"Tianjin Eye Hospital",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":50,"sex":15,"minAge":51,"maxAge":17,"enrollmentInfo":132,"targetDuration":4,"studyType":21,"phases":134,"briefSummary":135,"conditions":136,"keywords":137,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":42},"100522869","myopia-preventing-with-distance-image-screen-100522869","NCT06088225","Myopia Preventing With Distance-image Screen","Clinically Study the Ocular Axial Length and Sphere Equivalence Changes of Children With Distance-image Screen Usage for One Year","DIS","Inclusion Criteria:\n\n* (1) Must be 6\\~12 years old;\n* (2) Must be best corrected visual acuity \\\u003C logMAR: 0.1;\n* (3) Spherical Equivalence (SE) must be -1.00\\~ + 6.00 Diopter (D),\n* (4) Spherical Equivalence (SE) must have changed \\> 1.25 Diopter (D) in the recent 2 years;\n* (5) Must be astigmatism \\\u003C1.75 Diopter (D);\n* (6) Must be anisometropia \\\u003C1.75 Diopter(D).\n\nExclusion Criteria:\n\n* (1) Strabismus disease;\n* (2) Amblyopia disease;\n* (3) Cataract disease;\n* (4) Glaucoma disease;\n* (5) Severe dry eye disease;\n* (6) Cannot use distance-image screen for 12 month;\n* (7) Other severe diseases that would effect the use of distance-image screen.",{"count":133,"type":20},100,[23],"This study is for testing the efficacy and safety of distance-image screens for preventing myopia in children for 12 month. Each subjects would be asked to paired test the ocular parameters between before and after 12-month distance-image screens.",[26],[138],"Myopia; children","2023-10-20",{"date":141,"type":34},"2023-10-24",{"date":143,"type":34},"2022-10-01",{"date":145,"type":20},"2026-12-31",{"name":147,"class":97},"Beijing Airdoc Technology Co., Ltd.",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":15,"minAge":155,"maxAge":156,"enrollmentInfo":157,"targetDuration":4,"studyType":21,"phases":159,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":170,"locationsCount":4},"100497788","phase-1-efficacy-of-ivmed-85-on-pediatric-myopia-100497788","NCT05761795","Efficacy of IVMED-85 on Pediatric Myopia","A Randomized, Controlled, Double-Masked Adaptive Design Evaluation of the Safety and Preliminary Efficacy of IVMED-85 on Pediatric Myopia","Inclusion Criteria:\n\n* To be considered for enrollment in the study, the patient must meet all of the following criteria:\n\n  1. Age 5 to 16 years and 6 months, three age groups cohorts (5-8), (9-12), and (13-16) (Phase 1 patients will be exclusively age 13-16).\n  2. Refractive error by cycloplegic refraction in both eyes: myopia -0.75 D to -9.75 D spherical equivalent; astigmatism ≤ 4.00D; anisometropia \\\u003C3.00 D\n  3. Best corrected distance visual acuity better than or equal to Snellen 20\u002F40 (logMAR equivalent 0.3) in both eyes\n  4. Kmax \\>40 D and \\\u003C50 D in both eyes\n  5. Minimum corneal thickness \\> 350 microns in both eyes\n  6. Absence of ocular comorbidities (glaucoma, cataract, anterior segment dysgenesis, corneal scarring, juvenile rheumatoid arthritis, lens subluxation, uveitis, collagen disorders (Ehlers-Danlos, Marfan's syndrome, osteogenesis imperfecta, retinal diseases) in both eyes\n  7. Written informed consent from a parent or legal guardian and assent from participant\n  8. Willing and able to comply with clinic visits and study-related procedures.\n\n     Exclusion Criteria:\n\nA patient who meets any of the following criteria, in either eye, will be excluded from the study:\n\n1. Current or previous myopia treatment with atropine, pirenzepine, or other topical anti-muscarinic\n2. Significant central corneal scarring or hydrops\n3. Known copper allergy\n4. Use of rigid gas permeable lenses, including orthokeratology lenses within 90 days of screening\n5. Previous cornea, glaucoma, eyelid, strabismus (exotropia or esotropia) or intraocular surgeries\n6. Prior history of ocular disorder (e.g., current or prior history of strabismus (exotropia or esotropia), amblyopia, glaucoma, cataract, retinal detachment or nystagmus, or abnormality of the cornea, lens, iris, ciliary body, or central retina)\n7. Myopic degeneration with potential visual acuity worse than Snellen 20\u002F40 (logMAR equivalent 0.3)\n8. Intraocular pressure \\>26 mmHg\n9. Medical conditions pre-disposing patient to degenerative myopia or abnormal ocular refractive anatomy (e.g., Stickler Syndrome, Down Syndrome, osteogenesis imperfecta, Ehler's-Danlos Syndrome, Retinopathy of Prematurity)\n10. Participation in a clinical trial with use of any investigational drug or treatment within 30 days prior to Visit 1\n11. Employees of the study site or their immediate families\n12. Pregnancy\n13. Hypothyroidism or hyperthyroidism\n14. Patient less than 17 Kg weight\n15. Planned ophthalmic surgery during the study","5 Years","16 Years",{"count":158,"type":20},216,[160,161],"PHASE1","PHASE2","The goal of this clinical trial is to evaluate the safety and preliminary efficacy of a 1-year course of IVMED-85 eye drops for the treatment of pediatric myopia by assessing its safety effects on visual acuity and its effect on the change and\u002For progression of myopia.\n\nThe main question\\[s\\] it aims to answer are:\n\n* Does IVMED 85 improve visual acuity\n* Does IVMED 85 slow or otherwise change the progression of myopia\n\nParticipants will use eyedrops twice a day for one year. Researchers will compare IVMED 85 to a placebo.",[26],"2023-09-27",{"date":166,"type":34},"2023-09-29",{"date":168,"type":20},"2024-02",{"date":121,"type":20},{"name":171,"class":97},"iVeena Delivery Systems, Inc.",{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":15,"minAge":51,"maxAge":105,"enrollmentInfo":179,"targetDuration":4,"studyType":21,"phases":181,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":42},"100497416","myopia-control-combined-pbm-with-myopic-defocus-lens-in-children-100497416","NCT05756959","Myopia Control Combined PBM With Myopic Defocus Lens in Children","Myopia Control Combined PBM With Myopic Defocus Lens in Children: Double-blind RCT for 6 Month","Inclusion Criteria:\n\n* Informed consent by the supervision of the children\n* 6\\~13 years old (including both the 6 and 13)\n* SE range: -0.50\\~-5.50D\n* Astigmatism \\\u003C=2.00D\n* BCVA \\>=0.8\n* Anisometropia \\\u003C=1.50D\n* Confirmed to no use of other myopia control intervention\n\nExclusion Criteria:\n\n* Ocular lesions to effect vision or diseases (such as cataract, glaucoma, marcular pathology, cornea lesions, uveitis, retina detachment, congential opitc abnormal and etc.)\n* Halo, glare, toutic, ADHD, psoriasis\n* Systom disease: immune disease, central nerve system, Down syndrome, asthma, severe cardiopulmonary abnormal, severe liver and renal dysfunction.\n* Squint, ocular lesion or acute imflammation.\n* Other myopia control interventions within recent 3 month such as atropine, device, orthokeratology, multi-focus soft lens, multi-function spectacles.",{"count":180,"type":20},304,[23],"To study the efficacy of myopi control with two methods: low lever red light and peripheral defocus spectacles with four groups and design with prospective, double-blind, randimized, and with control for 6 month.",[26],"2023-03-07",{"date":186,"type":34},"2023-03-09",{"date":188,"type":34},"2022-12-12",{"date":190,"type":20},"2027-12-31",{"name":147,"class":97},{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":50,"sex":15,"minAge":199,"maxAge":200,"enrollmentInfo":201,"targetDuration":4,"studyType":21,"phases":203,"briefSummary":204,"conditions":205,"keywords":207,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":42},"100382122","choroidal-change-on-octa-in-eyes-with-high-myopia-100382122","NCT04255524","Choroidal Change on OCTA in Eyes With High Myopia","OCTA to Quantify the Parapapillary Choroidal Microvascular Changes in High Myopia","Inclusion Criteria:\n\n1. Spherical equivalent measurement can be included in above 4 groups\n2. Willing to be followed up in the future 10 years\n\nExclusion Criteria:\n\n1. Deny to sign the patient consent, or deny to be followed\n2. Evidence of cardiac, or diabetic, or CNS disease.\n3. Clinically diagnosed with retinal or choroidal disease\n4. Glucoma\n5. Cataract or corneal disease that influence the quality of fundus OCTA image","18 Years","55 Years",{"count":202,"type":20},200,[23],"Myopia is a global healthy concern, especially the high myopia and pathological myopia among Asian populations. However, its mechanism still remains largely unclear. Recent findings suggested choroidal changes might be related to the development of myopia. This study is to useOCT angiography (OCT-A) to investigate parapapillary choroidal microvasculature change in myopic eyes, and try to find the cause-and-effect relationship between choroidal change and the development of myopia.",[26,206],"Choroid Disease",[208,58,209],"OCTA","Choroid","2020-02-02",{"date":212,"type":34},"2020-02-05",{"date":214,"type":20},"2020-02-01",{"date":216,"type":20},"2030-12-31",{"name":218,"class":41},"The First Affiliated Hospital with Nanjing Medical University"]